What is OrthoFX?
OrthoFX operates at the intersection of medical technology and consumer health, specializing in advanced clear aligner systems. The company's comprehensive product suite, including AirFlex and FXClear, is engineered to optimize treatment efficiency and patient comfort. Beyond hardware, OrthoFX distinguishes itself through a robust digital infrastructure, featuring the FXOnTrack AI-powered platform for remote treatment oversight and the FXPay financial service, which streamlines the accessibility of orthodontic care for a diverse patient demographic.
By integrating sophisticated data analytics with clinical precision, the company provides dental practitioners with a scalable framework to deliver high-quality straightening solutions. This dual-focus approach—targeting both the clinical efficacy required by orthodontists and the convenience demanded by modern consumers—positions OrthoFX as a formidable player in the rapidly digitizing dental industry.
How much funding has OrthoFX raised?
OrthoFX has raised a total of $13M across 1 funding round:
Series A
$13M
Series A (2020): $13M with participation from SignalFire, Kairos, ShangBay Capital, and Unusual Ventures
Key Investors in OrthoFX
SignalFire
SignalFire is a venture capital firm designed as a technology company, utilizing a proprietary AI platform called Beacon AI to provide data-driven support and market intelligence to early-stage teams.
Unusual Ventures
Unusual Ventures is a Menlo Park-based firm that provides hands-on operational support through its Get Ahead Platform and educational workshops for founders.
ShangBay Capital
ShangBay Capital is an investment firm focused on identifying and supporting high-growth companies within the healthcare and life sciences sectors.
What's next for OrthoFX?
Looking ahead, the strategic deployment of this recent financing will likely focus on deepening the integration of AI within the FXOnTrack platform and expanding the company's footprint in the global dental market. As the firm transitions from its initial scaling phase into a more mature enterprise-level operation, the focus will shift toward optimizing supply chain logistics and broadening the adoption of its proprietary aligner materials.
The company is expected to prioritize the development of next-generation orthodontic tools that further reduce treatment duration while maintaining high clinical standards. With the support of its institutional backers, OrthoFX is poised to navigate the complexities of the healthtech sector, potentially exploring new partnerships or service expansions that reinforce its commitment to transforming the patient experience through technological innovation.
